bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1 -7 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
Authors: Loddick Sarah A. , Ross Sarah J. , Thomason Andrew G. , Robinson David M. , Walker Graeme E. , Dunkley Tom P.J. , Brave Sandra R. , Broadbent Nicola , Stratton Natalie C. , Trueman Dawn , Mouchet Elizabeth , Shaheen Fadhel S. , Jacobs Vivien N. , Cumberbatch Marie , Wilson Joanne , Jones Rhys D.O. , Bradbury Robert H. , Rabow Alfred , Gaughan Luke , Womack Chris , Barry Simon T. , Robson Craig N. , Critchlow Susan E. , Wedge Stephen R. , Brooks A. Nigel
Published: April 2023

PDF - 464KB, Supplementary Figure 1: Inhibition of AR transcripts with AZD3514 treated LNCaPs in steroid free media and the timecourse of AZD3514 effects in the presence and absence of DHT. Supplementary Figure 2: Effect of AZD3514 on growth of AR negative cells. Supplementary Figure 3: AR and PSA expression in LAPC4 cells treated with AZD3514. Supplementary Figure 4: AR degradation and synthesis rates of a C-terminal AR peptide, as measured by Mass Spectrometry. Supplementary Figure 5: Comparison of ARD1 & AZD3514 effects on seminal vesicle weight in rats, and pharmacokinetic effects in mice and rats Supplementary Figure 6: Effect of ARD1 on growth and AR in the HID28 model. Supplementary Figure 7: Dose response effects of AZD3514 on AR nuclear translocation and foci formation.
Supplementary Figure Legend from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
Authors: Eritja Nuria , Domingo Mónica , Dosil Maria Alba , Mirantes Cristina , Santacana Maria , Valls Joan , Llombart-Cussac Antonio , Matias-Guiu Xavier , Dolcet Xavier
Published: April 2023

PDF - 66K, Legends for Supplementary Figures 1 through 5.
Supplementary Tables 1 and 2 and Supplementary Figures 1 through 7 from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas
Authors: Bai Xue-Li , Zhang Qi , Ye Long-Yun , Hu Qi-Da , Fu Qi-Han , Zhi Xiao , Su Wei , Su Ri-Ga , Ma Tao , Chen Wei , Xie Shang-Zhi , Chen Cong-Lin , Liang Ting-Bo
Published: April 2023

PDF - 627K, Supplementary Table S1 IC50 values and statistical analyses of doxorubicin and doxorubicin plus LB-100 treatments in HCC cell lines; Supplementary Table S2: IC50 values and statistical analyses of cisplatin and cisplatin plus LB-100 treatments in HCC cell lines; Supplementary Figure S1: Toxicity of LB-100 in different cell lines; Supplementary Figure S2. Clonogenic assays of LB1 chemosensization; Supplementary Figure S3: PP2A_C overexpression attenuated LB-100 chemosensitization in vitro and in vivo; Supplementary Figure S4: Percentage of cells with abnormal nuclei; Supplementary Figure S5: PP2A activity is associated with VEGF secretion; Supplementary Figure S6: Pictures of HUVECs monolayers before and after doxorubicin treatment as indicated in Fig. 6A; Supplementary Figure S7: LB-100 facilitated early entry of doxorubicin into tumor cells.
Supplementary Figure 5 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 281KB, Apoptosis assay for RCC4 VHL (-) and VHL (+) cells treated with pentamidine 100 microM, olygomycin 1 microM, oxaprozin 300 microM and dopamine 1 microM.
Supplementary Figure 3 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 230KB, Evaluation of apoptosis in non-RCC cells treated with high scoring candidate drugs from the Connectivity Map.
Supplementary Figure 3 from FAK Inhibition Disrupts a β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth
Authors: Tancioni Isabelle , Uryu Sean , Sulzmaier Florian J. , Shah Nina R. , Lawson Christine , Miller Nichol L.G. , Jean Christine , Chen Xiao Lei , Ward Kristy K. , Schlaepfer David D.
Published: April 2023

PDF file - 112K, Pharmacological FAK inhibition decreases beta5 integrin and osteopontin (OPN) levels in ID8-IP cells in vivo.
Supplementary Figures S1-S6 from New Blocking Antibodies against Novel AGR2–C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice
Authors: Arumugam Thiruvengadam , Deng Defeng , Bover Laura , Wang Huamin , Logsdon Craig D. , Ramachandran Vijaya
Published: April 2023

Fig. S1. Extracellular rAGR2-mediated functions. Fig. S2. Candidate receptors binding and silencing. Fig. S3. Silencing C4.4A reduced basal and rAGR2-mediated functions. Fig. S4. Effects of AGR2 are mediated by C4.4A interacting with integrin B1. Fig. S5. Monoclonal antibodies developed bind respectively to AGR2 and C4.4A proteins and blocked their functions also. Fig. S6. In Vivo treatment with AGR2/C4.4A antibodies reduced tumor volume.
Supplementary Figure 2 from Zoledronic Acid Reverses the Epithelial–Mesenchymal Transition and Inhibits Self-Renewal of Breast Cancer Cells through Inactivation of NF-κB
Authors: Schech Amanda J. , Kazi Armina A. , Gilani Rabia A. , Brodie Angela H.
Published: April 2023

PDF file - 195K, Zoledronic acid prevents inhibits the number of existing mammospheres.
Supplementary Figure 3 from Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells
Authors: Filosto Simone , Baston David S. , Chung Samuel , Becker Cathleen R. , Goldkorn Tzipora
Published: April 2023

PDF file - 902K, Src binds to EGFR under CS exposure in a manner that is not exclusively dependent on Src or EGFR kinase activity. A. Serum starved A549 cells were incubated for 30' with 10 microM Src family kinase inhibitors, PP1-PP2 (5-5 microM), and then treated with CS, as before; Src was IPed from the total cell lysates and IBed for total Src and total EGFR. B. CHO cells transiently over-expressing wild-type (WT) or a kinase-dead (KD) K721A EGFR MT were exposed to EGF or CS, as before; EGFR was IPed and IBed for total receptor, total p-Y EGFR and p-Y416 Src.
Supplementary Figure 2 from Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells
Authors: Filosto Simone , Baston David S. , Chung Samuel , Becker Cathleen R. , Goldkorn Tzipora
Published: April 2023

PDF file - 359K, Aberrant CS-dependent activation of Src is inhibited by PP1 and PP2, Src Family Kinase (SFK) inhibitors. A549 cells were incubated (or not) for 30' with 10microM PP1-PP2 (5-5 microM) and then treated, or not (-), with EGF (100 ng/ml) or CS (smoke from 1 cigarette) for additional 30'. Active, p-Y416 Src and total Src were measured by IB in 50 microg of total proteins.
Supplementary Figure 5 from Effect of Niclosamide on Basal-like Breast Cancers
Authors: Londoño-Joshi Angelina I. , Arend Rebecca C. , Aristizabal Laura , Lu Wenyan , Samant Rajeev S. , Metge Brandon J. , Hidalgo Bertha , Grizzle William E. , Conner Michael , Forero-Torres Andres , LoBuglio Albert F. , Li Yonghe , Buchsbaum Donald J.
Published: April 2023

PDF file - 59KB, Supplementary Figure S5. In vivo toxicity study. Athymic nude mice were treated with niclosamide (20 mg/kg), TRA-8 (200 ng) or the combination for two weeks. Mice were weighed twice a week for two weeks.
Supplementary Figure 2 from Effect of Niclosamide on Basal-like Breast Cancers
Authors: Londoño-Joshi Angelina I. , Arend Rebecca C. , Aristizabal Laura , Lu Wenyan , Samant Rajeev S. , Metge Brandon J. , Hidalgo Bertha , Grizzle William E. , Conner Michael , Forero-Torres Andres , LoBuglio Albert F. , Li Yonghe , Buchsbaum Donald J.
Published: April 2023

PDF file - 209KB, Supplementary Figure S2. Niclosamide effect on Wnt/beta-catenin signaling. Activity of TCF/LEF plasmid reporter in the TOPflash assay was evaluated on adherent 2LMP, SUM159, HCC143 and HCC1187 cells. Cell lines were treated with 1 microM niclosamide for 24 hours (SUM159, HCC1143 and HCC1187) or with 0.25 microM niclosamide (2LMP). Each cell line was also treated with Wnt3A ligand (5 ng/mL) alone and in combination with niclosamide. The experiment was performed in triplicate. The bars represent means plus-minus SE. Treatment was compared to control or Wnt3A. Niclosamide vs. control (*P < 0.05), niclosamide vs. control (**P < 0.01), niclosamide vs. Wnt3A (#P < 0.05), niclosamide + Wnt3A vs. Wnt3A (##P < 0.01).
Supplementary Figure 3 from Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies
Authors: Yu Bing , Liu Wei , Yu Wen-Mei , Loh Mignon L. , Alter Shawn , Guvench Olgun , MacKerell Alexander D. , Tang Li-Da , Qu Cheng-Kui
Published: April 2023

PDF file - 111 KB, #220-324 inhibited SHP2-mediated cell signaling.
Supplementary Table 2 from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
Authors: Tahara Makiko , Inoue Takeshi , Sato Futoshi , Miyakura Yasuyuki , Horie Hisanaga , Yasuda Yoshikazu , Fujii Hirofumi , Kotake Kenjiro , Sugano Kokichi
Published: April 2023

PDF - 59K, SN-38 IC50 in the presence or absence of 10 nM olaparib in colon cancer cell lines.
Supplementary Table 1 from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
Authors: Tahara Makiko , Inoue Takeshi , Sato Futoshi , Miyakura Yasuyuki , Horie Hisanaga , Yasuda Yoshikazu , Fujii Hirofumi , Kotake Kenjiro , Sugano Kokichi
Published: April 2023

PDF - 156K, Mismatch repair, TP53, MRE11 and RAD50 gene status of colon cancer cell lines.
Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table Legends from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
Authors: Tahara Makiko , Inoue Takeshi , Sato Futoshi , Miyakura Yasuyuki , Horie Hisanaga , Yasuda Yoshikazu , Fujii Hirofumi , Kotake Kenjiro , Sugano Kokichi
Published: April 2023

PDF - 70K, Supplementary Materials and Methods, legends for Supplementary Figures 1 through 6, and legends for Supplementary Tables 1 through 6.
Supplementary Figure 5 from Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
Authors: Zhai Bo , Hu Fengli , Jiang Xian , Xu Jun , Zhao Dali , Liu Bing , Pan Shangha , Dong Xuesong , Tan Gang , Wei Zheng , Qiao Haiquan , Jiang Hongchi , Sun Xueying
Published: April 2023

PDF file - 225K, Supplementary Fig. S5.Interactions of Akt, autophagic and apoptotic pathways in sorafenib-resistant HCC cells.(A) Immunoblots of lysates of HepG2-SR and Huh7-SR cells following incubation with sorafenib (10 μM), GDC0068 (5 μM) or in combination for 48 h.
Supplementary Figure 4 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease
Authors: Zhong Lai-Ping , Zhu Dong-Wang , William William N. , Liu Ying , Ma Jie , Yang Cheng-Zhe , Yang Xiao , Wang Li-Zhen , Li Jiang , Myers Jeffrey N. , Lee J. Jack , Zhang Chen-Ping , Zhang Zhi-Yuan
Published: April 2023

PDF file - 3255K, Subgroup analysis of overall survival, disease-free survival, locoregional recurrence-free survival and distant metastasis free-survival in 232 OSCC patients with low and high cyclin D1 expression
Supplementary Table 4 from ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells
Authors: Wang Shu , Chen Xiangyun Amy , Hu Jing , Jiang Jian-kang , Li Yunfei , Chan-Salis Ka Yim , Gu Ying , Chen Gong , Thomas Craig , Pugh B. Franklin , Wang Yanming
Published: April 2023

CEBPB associated genes
Supplementary Table 3 from ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells
Authors: Wang Shu , Chen Xiangyun Amy , Hu Jing , Jiang Jian-kang , Li Yunfei , Chan-Salis Ka Yim , Gu Ying , Chen Gong , Thomas Craig , Pugh B. Franklin , Wang Yanming
Published: April 2023

ATF4 associated genes
Supplementary Figure 3 from Antitumor Effects in Gastrointestinal Stromal Tumors Using Photodynamic Therapy with a Novel Glucose-Conjugated Chlorin
Authors: Tanaka Mamoru , Kataoka Hiromi , Yano Shigenobu , Ohi Hiromi , Moriwaki Kazuhiro , Akashi Haruo , Taguchi Takahiro , Hayashi Noriyuki , Hamano Shingo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Joh Takashi
Published: April 2023

PDF file - 191KB, To determine the antitumor effects of a single H2TFPC-SGlc-mediated (single drug injection and irradiation) PDT on xenograft tumors in mice, mice were administered H2TFPC-SGlc at a dose of 1.25 micromol/kg by i.v. 10 days after tumor inoculation and then irradiated with 660 nm LED light at 40 J/cm2.
Supplementary Figure 1 from Antitumor Effects in Gastrointestinal Stromal Tumors Using Photodynamic Therapy with a Novel Glucose-Conjugated Chlorin
Authors: Tanaka Mamoru , Kataoka Hiromi , Yano Shigenobu , Ohi Hiromi , Moriwaki Kazuhiro , Akashi Haruo , Taguchi Takahiro , Hayashi Noriyuki , Hamano Shingo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Joh Takashi
Published: April 2023

PDF file - 185KB, GIST-T1 and WI-38 cells were incubated in high, normal or non glucose medium with 1 microM of glucose (2-NBDG) or H2TFPC-SGlc for various timepoints, and the uptake of the drugs were estimated by FACS.
Supplementary Figure 3 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Authors: Foster Paul , Yamaguchi Kyoko , Hsu Pin P. , Qian Fawn , Du Xiangnan , Wu Jianming , Won Kwang-Ai , Yu Peiwen , Jaeger Christopher T. , Zhang Wentao , Marlowe Charles K. , Keast Paul , Abulafia Wendy , Chen Jason , Young Jenny , Plonowski Artur , Yakes F. Michael , Chu Felix , Engell Kelly , Bentzien Frauke , Lam Sanh T. , Dale Stephanie , Yturralde Olivia , Matthews David J. , Lamb Peter , Laird A. Douglas
Published: April 2023

Effects of XL147 on PI3K Signaling Pathway in OVCAR-3 and U87-MG cells.
Supplementary Figure 2 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Authors: Foster Paul , Yamaguchi Kyoko , Hsu Pin P. , Qian Fawn , Du Xiangnan , Wu Jianming , Won Kwang-Ai , Yu Peiwen , Jaeger Christopher T. , Zhang Wentao , Marlowe Charles K. , Keast Paul , Abulafia Wendy , Chen Jason , Young Jenny , Plonowski Artur , Yakes F. Michael , Chu Felix , Engell Kelly , Bentzien Frauke , Lam Sanh T. , Dale Stephanie , Yturralde Olivia , Matthews David J. , Lamb Peter , Laird A. Douglas
Published: April 2023

Assessment of effects of XL147 on Nutrient-Dependent mTOR Signaling Pathway in Ramos cells.
Supplementary Materials and Methods, Supplementary Table 1, and Supplementary Figure Legends from Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines In Vitro and In Vivo
Authors: Huang Lynn Y.L. , Chang Chia-Chi , Lee Ying-Shuan , Chang Jia-Ming , Huang Jiann-Jyh , Chuang Shih-Hsien , Kao Kuo-Jang , Lau Gillian M.G. , Tsai Pei-Yi , Liu Chia-Wei , Lin Her-Sheng , Lau Johnson Y.N.
Published: April 2023

PDF - 126K, Includes the methods for preparation of TAI-95, drug-drug synergy experiments, and preliminary subacute toxicology, Table S1: Combination index of TAI-95 with anticancer agents, and supplementary figure legends.
Supplemental Figure S1 from Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts
Authors: Pei Nana , Wan Renqiang , Chen Xinglu , Li Andrew , Zhang Yanling , Li Jinlong , Du Hongyan , Chen Baihong , Wei Wenjin , Qi Yanfei , Zhang Yi , Katovich Michael J. , Sumners Colin , Zheng Haifa , Li Hongwei
Published: April 2023

Supplemental Figure S1. Ang-(1-7) inhibited migration of NPC cells.
Supplementary Figures 9 and 10 from MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer
Authors: Muñoz-Galván Sandra , Gutierrez Gabriel , Perez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure S9 - ROS scavengers recovers bortezomib-induced p-NFkB nuclear translocation in MAP17-expressing cells. Supplementary Figure S10 - ROS scavengers recovers bortezomib-induced total NFkB nuclear translocation in MAP17-expressing cells. Supplementary Figure S10 - ROS scavengers recovers bortezomib-induced total NFkB nuclear translocation in MAP17-expressing cells.
Supplementary Figures 6 - 7 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Authors: Jiang Ning , Wang Dongsheng , Hu Zhongliang , Shin Hyung Ju C. , Qian Guoqing , Rahman Mohammad Aminur , Zhang Hongzheng , Amin A.R.M. Ruhul , Nannapaneni Sreenivas , Wang Xiaojing , Chen Zhengjia , Garcia Gabriela , MacBeath Gavin , Shin Dong M. , Khuri Fadlo R. , Ma Jun , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

PDF file - 520KB, Supplementary Figure 6. CM combination inhibits EGFR and HER3 signaling activation in vivo. Supplementary Figure 7. Inhibition of pHER3 and pAKT expression by CM combination.
Supplementary Tables 1 to 3 and Supplementary Figures 1 to 7 from Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2
Authors: Liu Suhu , Walker Sarah R. , Nelson Erik A. , Cerulli Robert , Xiang Michael , Toniolo Patricia A. , Qi Jun , Stone Richard M. , Wadleigh Martha , Bradner James E. , Frank David A.
Published: April 2023

PDF - 128K, Supplemental Table 1: Clinical and molecular characteristics of cell lines; Supplemental Table 2: Sequences of primers used for Q-RT-PCR and CHIP; Supplemental Table 3: Targeting sequences of shRNA constructs; Supplemental Figure S1: JQ1 inhibits STAT5-dependent gene expression; Supplemental Figure S2: JQ1 inhibits expression of endogenous STAT5 target genes; Supplemental Figure S3: RNA interference constructs targeting bromodomain proteins show specificity; Supplemental Figure S4: Among bromodomain proteins, only inhibition of Brd2 reduces STAT5 transcriptional function; Supplemental Figure S5: Brd2 depletion reduces expression of STAT5 target genes only in cells with constitutively active STAT5. shRNA to Brd2 or GFP (as a control) was introduced into cells with (A) or without (B) activated STAT5, and quantitative RT-PCR analysis was performed for the indicated genes; Supplemental Figure S6: A. JQ1 reduces viability of T lymphocytic leukemia cells. B. JQ1 reduces Myc protein expression in T-ALL; Supplemental Figure S7. A. JQ1 has minimal effects on the viability of mononuclear cells from human cord blood. B. Kinase inhibitors have minimal effects on the viability of mononuclear cells from human cord blood.
Supplementary Table 3 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
Authors: Unger Gretchen M. , Kren Betsy T. , Korman Vicci L. , Kimbrough Tyler G. , Vogel Rachel I. , Ondrey Frank G. , Trembley Janeen H. , Ahmed Khalil
Published: April 2023

PDF - 46K, Origin and characteristics of tumor cell lines used in HNSCC survival studies.
Supplementary Table 1 from On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients
Authors: Schwaederle Maria , Daniels Gregory A. , Piccioni David E. , Fanta Paul T. , Schwab Richard B. , Shimabukuro Kelly A. , Parker Barbara A. , Kurzrock Razelle
Published: April 2023

Supplemental Table 1. Frequency of Molecular Alterations in 439 Patients
Supplementary Figure 2 from Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Authors: Tan Nguyen , Wong Maureen , Nannini Michelle A. , Hong Rebecca , Lee Leslie B. , Price Stephen , Williams Karen , Savy Pierre Pascal , Yue Peng , Sampath Deepak , Settleman Jeffrey , Fairbrother Wayne J. , Belmont Lisa D.
Published: April 2023

PDF file - 558K, Biochemical Selectivity of G-963. Percent inhibition of various kinases treated with 1uM G-963. Assays were performed at Invitrogen using their SelectScreenR Kinase profiling service
Supplementary Figure 6 from Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Authors: Magin Simon , Papaioannou Maria , Saha Janapriya , Staudt Christian , Iliakis George
Published: April 2023

Supplementary Figure 6. Knockdown of Rad51 reveals the actual effect of araA on SSA, as measured in U2OS 283C cells by GFP analysis
Supplementary Figure 4 from Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Authors: Magin Simon , Papaioannou Maria , Saha Janapriya , Staudt Christian , Iliakis George
Published: April 2023

Supplementary Figure 4. Effect of araA on HRR as measured in DRaa40 Chinese hamster cells by means of an integrated DR-GFP reporter construct
Supplementary Table 1 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Authors: Marín-Aguilera Mercedes , Codony-Servat Jordi , Reig Òscar , Lozano Juan José , Fernández Pedro Luis , Pereira María Verónica , Jiménez Natalia , Donovan Michael , Puig Pere , Mengual Lourdes , Bermudo Raquel , Font Albert , Gallardo Enrique , Ribal María José , Alcaraz Antonio , Gascón Pere , Mellado Begoña
Published: April 2023

PDF - 72K, Genes expression values by qRT-PCR in treated patients vs non-treated patients; TLDA: TaqMan Low Density Arrays; FDR: False Discovery Rate.
Supplementary Figure Legends from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Authors: Marín-Aguilera Mercedes , Codony-Servat Jordi , Reig Òscar , Lozano Juan José , Fernández Pedro Luis , Pereira María Verónica , Jiménez Natalia , Donovan Michael , Puig Pere , Mengual Lourdes , Bermudo Raquel , Font Albert , Gallardo Enrique , Ribal María José , Alcaraz Antonio , Gascón Pere , Mellado Begoña
Published: April 2023

PDF - 35K, Legends for Supplementary Figures 1 and 2.
Supplementary Figure 2 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Authors: Marín-Aguilera Mercedes , Codony-Servat Jordi , Reig Òscar , Lozano Juan José , Fernández Pedro Luis , Pereira María Verónica , Jiménez Natalia , Donovan Michael , Puig Pere , Mengual Lourdes , Bermudo Raquel , Font Albert , Gallardo Enrique , Ribal María José , Alcaraz Antonio , Gascón Pere , Mellado Begoña
Published: April 2023

PDF - 475K, Radiological-progression analysis according to gene expression levels of markers differentially expressed in treated vs non-treated patients.
Supplemental Fig 1,2,3 from Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
Authors: Junttila Melissa R. , Devasthali Vidusha , Cheng Jason H. , Castillo Joseph , Metcalfe Ciara , Clermont Anne C. , Otter Douglas Den , Chan Emily , Bou-Reslan Hani , Cao Tim , Forrest William , Nannini Michelle A. , French Dorothy , Carano Richard , Merchant Mark , Hoeflich Klaus P. , Singh Mallika
Published: April 2023

Supplemental Fig 1,2,3. Tumor growth rates, overall survival and single agent GDC-0973 in vitro response
Supplementary Figures 1-4 from Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma
Authors: Abraham Jinu , Prajapati Suresh I. , Nishijo Koichi , Schaffer Beverly S. , Taniguchi Eri , Kilcoyne Aoife , McCleish Amanda T. , Nelon Laura D. , Giles Francis G. , Efstratiadis Argiris , LeGallo Robin D. , Nowak Brent M. , Rubin Brian P. , Malempati Suman , Keller Charles
Published: April 2023

Supplementary Figures 1-4 from Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma
Supplementary Figure Legends, Materials and Methods, and Table 1 from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma
Authors: Gonzalez-Villasana Vianey , Rodriguez-Aguayo Cristian , Arumugam Thiruvengadam , Cruz-Monserrate Zobeida , Fuentes-Mattei Enrique , Deng Defeng , Hwang Rosa F. , Wang Huamin , Ivan Cristina , Garza Raul Joshua , Cohen Evan , Gao Hui , Armaiz-Pena Guillermo N. , del C. Monroig-Bosque Paloma , Philip Bincy , Rashed Mohammed H. , Aslan Burcu , Erdogan Mumin Alper , Gutierrez-Puente Yolanda , Ozpolat Bulent , Reuben James M. , Sood Anil K. , Logsdon Craig , Lopez-Berestein Gabriel
Published: April 2023

Supplementary Figure Legends, Materials and Methods, and Table 1. Supplementary Figure Legends, Supplementary Material and Methods for RNA isolation, cDNA synthesis, and quantification of RNA species, Supplementary Table 1. Primer Sequences.
Supplementary Figure 3 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
Authors: Smith Rosamund C. , Cramer Martin S. , Mitchell Pamela J. , Capen Andrew , Huber Lysiane , Wang Rong , Myers Laura , Jones Bryan E. , Eastwood Brian J. , Ballard Darryl , Hanson Jeff , Credille Kelly M. , Wroblewski Victor J. , Lin Boris K. , Heuer Josef G.
Published: April 2023

Supplementary Figure 3. LSN2478185 reduces the loss of skeletal muscle mass under conditions of caloric restriction.
Figure S6 from Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway
Authors: Dhanyamraju Pavan Kumar , Holz Philipp Simon , Finkernagel Florian , Fendrich Volker , Lauth Matthias
Published: April 2023

This file contains images of mice with xenograft samples at the end of the experiment.
Supplementary Table S3b from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

List of secondary antibodies.
Figure S3 from Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway
Authors: Dhanyamraju Pavan Kumar , Holz Philipp Simon , Finkernagel Florian , Fendrich Volker , Lauth Matthias
Published: April 2023

This file contains additional experiments on the function of HDAC6 in Hedgehog signaling in various cell lines.
Supplementary Figure 3 from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

Analysis of stemmness genes after 5 days of dacomitinib treatment.
Supplementary Figure 2 from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

Analysis of EGFR signaling after long term dacomitinib treatment.
Supplementary Table 2 from Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78
Authors: Mo Lihong , Bachelder Robin E. , Kennedy Margaret , Chen Po-Han , Chi Jen-Tsan , Berchuck Andrew , Cianciolo George , Pizzo Salvatore V.
Published: April 2023

Stemness genes
Supplementary figure S2 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
Authors: Ju Huai-Qiang , Gocho Takeshi , Aguilar Mitzi , Wu Min , Zhuang Zhuo-Nan , Fu Jie , Yanaga Katsuhiko , Huang Peng , Chiao Paul J.
Published: April 2023

Supplementary figure S2. siRNA depletion of NF-κB/p65 decreased cellular ROS levels in MIAPaCa-2/GR cells or MIAPaCa-2 cells treated with gemcitabine.
Supplementary Figure 5 from Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78
Authors: Mo Lihong , Bachelder Robin E. , Kennedy Margaret , Chen Po-Han , Chi Jen-Tsan , Berchuck Andrew , Cianciolo George , Pizzo Salvatore V.
Published: April 2023

MemGRP78 positive tumor cells have a lower proliferation rate
Supplementary Figure 4 from Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78
Authors: Mo Lihong , Bachelder Robin E. , Kennedy Margaret , Chen Po-Han , Chi Jen-Tsan , Berchuck Andrew , Cianciolo George , Pizzo Salvatore V.
Published: April 2023

MemGRP78 positive tumor cells have a lower proliferation rate
Supplemental Figure Legends from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
Authors: Regina Anthony , Demeule Michel , Tripathy Sasmita , Lord-Dufour Simon , Currie Jean-Christophe , Iddir Mustapha , Annabi Borhane , Castaigne Jean-Paul , Lachowicz Jean E.
Published: April 2023

Legends to supplemental figures 1-4.
Supplemental Figure 2 from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
Authors: Regina Anthony , Demeule Michel , Tripathy Sasmita , Lord-Dufour Simon , Currie Jean-Christophe , Iddir Mustapha , Annabi Borhane , Castaigne Jean-Paul , Lachowicz Jean E.
Published: April 2023

SDS-PAGE of anti-HER2 and ANG4043 under reducing conditions with Coomassie Blue staining and immunodetection of An2 by WB. The An2 peptide is associated with two distinct bands corresponding to heavy and light chains of ANG4043.
Supplementary Tables S1-S3 and Supplementary Figures S1-S8 from The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer
Authors: Ibuki Naokazu , Ghaffari Mazyar , Reuveni Hadas , Pandey Mitali , Fazli Ladan , Azuma Haruhito , Gleave Martin E. , Levitzki Alexander , Cox Michael E.
Published: April 2023

Supplementary Table and Figures: Table S1: Prostate cancer tumor microarray characteristics Fig. S1: IRS antibody validation Fig. S2: Effect of NT157 on the viability of benign prostatic cell line Fig. S3: Immunoblot analysis of cell cycle markers Fig. S4: NT157 inhibits LNCaP xenograft growth and delays CRPC Table S2: Growth rate calculation for NT157 treated xenografts Fig. S5: NT157 treatment of LNCaP Xenograft has no effect on mice body weight Fig. S6: NT157 potentiates docetaxel activity in PC3 xenografts Table S3: Growth rate calculation for NT157 and Docetaxel treated PCs xenografts Fig. S7: Growth rate calculation for NT157 and Docetaxel treated PCs xenografts Fig. S8: NT157 treatment of PC3 xenograft tumors has no effect on mice body weight
Supplementary Figure S6 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) cells is associated with activation of MAPK/ERK pathway.
Supplemental materials, Figure 1 from Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D
Authors: Jeong Youngtae , Swami Srilatha , Krishnan Aruna V. , Williams Jasmaine D. , Martin Shanique , Horst Ronald L. , Albertelli Megan A. , Feldman Brian J. , Feldman David , Diehn Maximilian
Published: April 2023

Supplemental materials, Figure 1. Supplemental Fig. 1. Effect of calcitriol on Wnt gene expression
Supplemental Figure 3 from Radioprotection of the Brain White Matter by Mn(III) N-Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP5+
Authors: Weitzel Douglas H. , Tovmasyan Artak , Ashcraft Kathleen A. , Rajic Zrinka , Weitner Tin , Liu Chunlei , Li Wei , Buckley Anne F. , Prasad Mark R. , Young Kenneth H. , Rodriguiz Ramona M. , Wetsel William C. , Peters Katherine B. , Spasojevic Ivan , Herndon James E. , Batinic-Haberle Ines , Dewhirst Mark W.
Published: April 2023

Supplemental Figure 3: Effects of radiation and MnTnBuOE-2-PyP5+ on tumor cells. (A) LN-18 and (B) LN-229 glioblastoma cell lines treated with or without 50 nM MnTnBuOE-2-PyP5+ in clonogenic survival assays prior to various doses of radiation.
Supplementary Methods, Table S1 and Figures S1-S3 from High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody–Drug Conjugates
Authors: de Goeij Bart E.C.G. , Satijn David , Freitag Claudia M. , Wubbolts Richard , Bleeker Wim K. , Khasanov Alisher , Zhu Tong , Chen Gary , Miao David , van Berkel Patrick H.C. , Parren Paul W.H.I.
Published: April 2023

Supplementary Method S1: Quantitative determination of cell surface antigens. Supplementary Method S2: Synthesis of Duostatin-3. Supplementary Table S1: Apparent antibody affinities. Supplementary Figure S1: Distribution of HER2, EGFR and TF in unstimulated HCC1954 cells. Supplementary Figure S2: Endosomal and lysosomal colocalisation of TF, EGFR and HER2 in tumor cells after treatment with target-specific antibodies. Supplementary Figure S3: Flow cytometry analysis of SK-OV-3 cells after ADC-treatment.
Data Supplement from Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma
Authors: Balbous Anaïs , Renoux Brigitte , Cortes Ulrich , Milin Serge , Guilloteau Karline , Legigan Thibaut , Rivet Pierre , Boissonnade Odile , Martin Sébastien , Tripiana Caroline , Wager Michel , Bensadoun René Jean , Papot Sébastien , Karayan-Tapon Lucie
Published: April 2023

Supplementary Figure 2: CGP-2 had no effect on H9-NSC viability.
Supplementary Figure 2 from USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry
Authors: Liu Tieju , Sun Baocun , Zhao Xiulan , Li Yanlei , Zhao Xueming , Liu Ying , Yao Zhi , Gu Qiang , Dong Xueyi , Shao Bing , Lin Xian , Liu Fang , An Jindan
Published: April 2023

Supplementary Figure 2. AURKA overexpression induced extra centrosomes, ALDH1 positivity and USP44 upregulation.
Data Supplement from An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
Authors: Astin Jonathan W. , Jamieson Stephen M.F. , Eng Tiffany C.Y. , Flores Maria V. , Misa June P. , Chien Annie , Crosier Kathryn E. , Crosier Philip S.
Published: April 2023

Video S2. Confocal time-lapse imaging of a lyve1:egfp embryo from 30 hpf to 49:42 hpf (19:42h) treated with 30 μM kaempferol. Time-lapse image z-stacks were collected 10 min apart; movie was made at 7 frames per second.
Supplementary Figures 1 through 3 from A Chemically Defined Trifunctional Antibody–Cytokine–Drug Conjugate with Potent Antitumor Activity
Authors: List Thomas , Casi Giulio , Neri Dario
Published: April 2023

Supplementary Figure S1: Immunofluorescent staining, using F8 antibody fragments, of tumor sections from F9 and C1498 tumors excised from 129Sv and C57BL/6 mice. Supplementary Figure S2: The architecture of the genetic constructs encoding F8-IL2, F8-IL2-SH and F8-SH in pcDNA3.1+ (Invitrogen) backbone and the nucleotide sequences for the three constructs used in this study. Supplementary Figure S3: Individual tumor sizes in high and low dose therapy groups with C57BL/6 mice bearing C1498 tumors or 129Sv mice bearing F9 tumors.
Supplementary Figure 2 from Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts
Authors: Paulitschke Verena , Berger Walter , Paulitschke Philipp , Hofstätter Elisabeth , Knapp Bernhard , Dingelmaier-Hovorka Ruth , Födinger Dagmar , Jäger Walter , Szekeres Thomas , Meshcheryakova Anastasia , Bileck Andrea , Pirker Christine , Pehamberger Hubert , Gerner Christopher , Kunstfeld Rainer
Published: April 2023

Proteome characterization of Vemurafenib-sensitive and-resistant melanoma cells V0 and V1 of nuclear fraction. Left: Hierarchical clustering of Z-scored expression values for significantly changed proteins, revealing differences between V0 and V1. Left: Profiles of the five main clusters. Two clusters with the highest difference are selected and the significant regulated groups are depicted. Red: upregulated in V1, green: downregulated in V1.
Supplementary Table 1 from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file contains details of the reaction conditions for determining glycolytic isoenzyme kinetics
Figure S5 from Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma
Authors: Li Nan , Maly Dustin J. , Chanthery Yvan H. , Sirkis Daniel W. , Nakamura Jean L. , Berger Mitchel S. , James C. David , Shokat Kevan M. , Weiss William A. , Persson Anders I.
Published: April 2023

Figure S5. Body weight of mice xenografted with human primary GBM cells following treatment with combinations of radiotherapy and VX680 treatment.
Figure S3 from Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma
Authors: Li Nan , Maly Dustin J. , Chanthery Yvan H. , Sirkis Daniel W. , Nakamura Jean L. , Berger Mitchel S. , James C. David , Shokat Kevan M. , Weiss William A. , Persson Anders I.
Published: April 2023

Figure S3. Inhibition of phosphorylated histone H3 following incubation with the pan-AURK inhibitor VX680 in human primary GBM43 cultures.
Supplementary Figure S2 from Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells
Authors: Telford Bryony J. , Chen Augustine , Beetham Henry , Frick James , Brew Tom P. , Gould Cathryn M. , Single Andrew , Godwin Tanis , Simpson Kaylene J. , Guilford Parry
Published: April 2023

Supplementary Figure S2. HDAC inhibitor and Taxol combinations.
Supplemental materials and methods from Inhibition of ABCB1 Overcomes Cancer Stem Cell–like Properties and Acquired Resistance to MET Inhibitors in Non–Small Cell Lung Cancer
Authors: Sugano Teppei , Seike Masahiro , Noro Rintaro , Soeno Chie , Chiba Mika , Zou Fenfei , Nakamichi Shinji , Nishijima Nobuhiko , Matsumoto Masaru , Miyanaga Akihiko , Kubota Kaoru , Gemma Akihiko
Published: April 2023

Cell lines and drugs Clinical samples and Immunohistochemical staining
Supplemental Table 1. Supplemental Table 2. Supplemental Table 3. from Inhibition of ABCB1 Overcomes Cancer Stem Cell–like Properties and Acquired Resistance to MET Inhibitors in Non–Small Cell Lung Cancer
Authors: Sugano Teppei , Seike Masahiro , Noro Rintaro , Soeno Chie , Chiba Mika , Zou Fenfei , Nakamichi Shinji , Nishijima Nobuhiko , Matsumoto Masaru , Miyanaga Akihiko , Kubota Kaoru , Gemma Akihiko
Published: April 2023

Supplemental Table 1. Gene copy numbers of MET, EGFR and KRAS in EBC-1R cells Supplemental Table 2. MiRNAs correlated with the sensitivity to PHA665752 Supplemental Table 3. ABCB1 protein expression in 50 lung squamous cell cancer patientsã€€
Supplementary Figure S3 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
Authors: Ramirez Yulian P. , Mladek Ann C. , Phillips Roger M. , Gynther Mikko , Rautio Jarkko , Ross Alonzo H. , Wheelhouse Richard T. , Sakaria Jann N.
Published: April 2023

Supplementary Figure S3. MGMT sensitivity of anti-glioma activity of TMZ, DP86 and DP68. (A-B) TMZ, DP68, and DP86 dose-response curves in (A) U118NS and (B) U87NSTMZ cell lines. All neurosphere lines were plated in triplicate and exposed to varying concentrations of each agent. Following a7-day incubation neurospheres were quantified. Representative results from three independent experiments are shown. (C) GBM12 cells were plated with varying densities, treated with no drug (control), 1 microM DP68, 3 microM DP68 or 4 microM TMZ. Neurospheres were counted after 14 days. (D-E) T98G (D) and GBM6 (E) cultures were co-treated with 0 or 10 microM O6-BG and response to TMZ was evaluated. Cell survival was analyzed via CyQuant assay with the mean relative fluorescence {plus minus} SEM from three independent experiments are shown.
Supplementary Figure Legends from Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer
Authors: Patterson Andrea M. , Kaabinejadian Saghar , McMurtrey Curtis P. , Bardet Wilfried , Jackson Ken W. , Zuna Rosemary E. , Husain Sanam , Adams Gregory P. , MacDonald Glen , Dillon Rachelle L. , Ames Harold , Buchli Rico , Hawkins Oriana E. , Weidanz Jon A. , Hildebrand William H.
Published: April 2023

Supplementary Figure Legends for S1-S3.
Supplementary Movie from Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
Authors: Huang Qingling , Schneeberger Valentina E. , Luetteke Noreen , Jin Chengliu , Afzal Roha , Budzevich Mikalai M. , Makanji Rikesh J. , Martinez Gary V. , Shen Tao , Zhao Lichao , Fung Kar-Ming , Haura Eric B. , Coppola Domenico , Wu Jie
Published: April 2023

microCT scans
Supplementary Table S5: Differentially Methylated CpG Sites (2173 Sites) in 24 NPC and 24 NCNBT from Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma
Authors: Jiang Wei , Liu Na , Chen Xiao-Zhong , Sun Ying , Li Bin , Ren Xian-Yue , Qin Wei-Feng , Jiang Ning , Xu Ya-Fei , Li Ying-Qin , Ren Jian , Cho William CS , Yun Jing-Ping , Zeng Jing , Liu Li-Zhi , Li Li , Guo Ying , Mai Hai-Qiang , Zeng Mu-Sheng , Kang Tie-Bang , Jia Wei-Hua , Shao Jian-Yong , Ma Jun
Published: April 2023

Differentially Methylated CpG Sites (2173 Sites) in 24 Nasopharyngeal Carcinoma (NPC) Tissues and 24 Non-cancer Nasopharyngitis Biopsy Tissues (NCNBT)
Supplementary Figures S1-S4 and Tables S1-S2 from Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
Authors: Floc'h Nicolas , Ashton Susan , Taylor Paula , Trueman Dawn , Harris Emily , Odedra Rajesh , Maratea Kim , Derbyshire Nicola , Caddy Jacqueline , Jacobs Vivien N. , Hattersley Maureen , Wen Shenghua , Curtis Nicola J. , Pilling James E. , Pease Elizabeth J. , Barry Simon T.
Published: April 2023

Supplementary figues and tables: Figure S1. In vitro AZD1152-hQPA reduces proliferation and induces polyploidy across a panel of human AML cancer cell lines. Figure S2. AZD1152 has a modest effect on the growth of the HL-60 xenograft models in SCID mice Figure S3. AZD1152 in combination with Ara-C has a modest effect on the growth of the HL-60 xenograft models in SCID mice Figure S4. AZD2811 affect the neutrophil count in a dose-dependent manner Table S1: Cytogenetics of the different cell lines Table S2: Summary table of the pIC50 and nuclear area.
Supplementary Figure Legends from Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate–Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma
Authors: Liu Chia-Wen , Hua Kuo-Tai , Li Kai-Chun , Kao Hsiang-Fong , Hong Ruey-Long , Ko Jenq-Yuh , Hsiao Michael , Kuo Min-Liang , Tan Ching-Ting
Published: April 2023

This file contains the supplementary figure legends
Supplementary Figure 7 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Authors: Sano Yuji , Hashimoto Eri , Nakatani Noriaki , Abe Masaichi , Satoh Yasuko , Sakata Kiyoaki , Fujii Toshihiko , Fujimoto-Ouchi Kaori , Sugimoto Masamichi , Nagahashi Shigehisa , Aoki Masahiro , Motegi Hiroshi , Sasaki Eiichi , Yatabe Yasushi
Published: April 2023

Supplementary Figure 7. Comparison of MET protein levels in HGF-autocrine cell lines with those in representative standard cell lines for MET-IHC scoring.
Figure S3 from Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
Authors: Le Clorennec Christophe , Bazin Hervé , Dubreuil Olivier , Larbouret Christel , Ogier Charline , Lazrek Yassamine , Garambois Véronique , Poul Marie-Alix , Mondon Philippe , Barret Jean-Marc , Mathis Gérard , Prost Jean-François , Pèlegrin André , Chardès Thierry
Published: April 2023

Supplemental Fig.S3. In pancreatic cancer cells, ch9F7-F11-Emb is a negative allosteric modulator of NRG1-mediated signaling. The low-fucose non-NRG1 competing allosteric anti-HER3 antibody ch9F7-F11-Emb inhibits in a dose-dependent manner NRG1-mediated cell signaling more efficiently than the ligand-competing H4B-121-Emb antibody. BxPC3 cells were pre-stimulated with 1nM NRG1 for 5min, before adding antibodies at various concentrations for another 25min. After cell lysis, the expression levels of total and phosphorylated HER3 (Tyr1289, Tyr1197 and Tyr1222), and total and phosphorylated AKT (Ser473) were measured by western blotting (A) using the appropriate antibodies. Phosphorylation was then pixel-quantified with Image J (B) and shown relative to the maximal phosphorylation (100%) evaluated in NRG1-stimulated cells without antibody treatment (M). Results are the mean {plus minus} SD of three independent experiments
Supplementary Figures 1 through 8 from Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
Authors: Brady Samuel W. , Zhang Jian , Seok Daniel , Wang Hai , Yu Dihua
Published: April 2023

PDF - 299K, Supplementary Figure 1. HER3 activation is not increased in LapR cells. Supplementary Figure 2. Time-independent maintenance of phospho-Akt during lapatinib treatment in BT474 LapR cells. Supplementary Figure 3. p110α knockdown sensitizes lapatinib-resistant cells to lapatinib. Supplementary Figure 4. p110α knockdown is more effective in BT474 LapR cells than UACC893 LapR cells. Supplementary Figure 5. Wild-type and mutant p110α promote basal proliferation. BT474 cells stably infected with indicated p110α constructs were grown for 4 days. Supplementary Figure 6. Analysis of combination treatment synergy. Supplementary Figure 7. Lapatinib plus BYL719 inhibits HER3. Supplementary Figure 8. Lapatinib plus BYL719 does not induce weight loss.
Supplementary Figure 4 from Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation
Authors: Neel Nicole F. , Stratford Jeran K. , Shinde Vaishali , Ecsedy Jeffrey A. , Martin Timothy D. , Der Channing J. , Yeh Jen Jen
Published: April 2023

PDF - 21K, HH3 staining.
Supplementary Figure 9 from Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
Authors: Brady Samuel W. , Zhang Jian , Seok Daniel , Wang Hai , Yu Dihua
Published: April 2023

PDF - 308K, Supplementary Figure 9. Inhibition of Akt and Erk phosphorylation in vivo by combination treatment.
Supplementary Figure 7 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Figure 7. Detection of NK150460 and its metabolites in whole cell extract and culture medium in vitro.